CME Information
Provider Statement: This continuing medical education activity is provided by 
.
Support Statement: This activity is supported by an educational grant from Merck & Co., Inc.
Target Audience: The intended audience for this activity is gastroenterologists and other health care professionals involved in the treatment of patients with inflammatory bowel disease (IBD).
Learning Objectives: Upon successful completion of this activity, participants should be better able to:
- Incorporate the latest information about biologics for IBD patients
- Compare biosimilars to both small-molecule generic therapies and their reference biologic based on structure, manufacturing, regulation, and/or clinical properties
- Review the latest safety and efficacy data regarding the use of biologics relevant to IBD
- Describe strategies to educate patients regarding biologics and the importance of open communication regarding their concerns
Activity Chair:
David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
Faculty:
Iris Dotan, MD
Director, Division of Gastroenterology
Rabin Medical Center, Beilinson Hospital
Petah Tikva, Israel
Sackler Faculty of Medicine, Tel Aviv University
President, Israeli Association of Gastroenterology and Liver Diseases
Tel Aviv, Israel
Bruce E. Sands, MD, MS
Chief, Dr. Henry D. Janowitz Division of Gastroenterology
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai Hospital and Mount Sinai Health System
New York, NY
Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, July 20, 2018 through July 19, 2019.
How to Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, review the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, the American Gastroenterological Association will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Activity Chair and Faculty members report the following relationship(s):
David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Consulting Fee: AbbVie, Abgenomics, Allergan, Amgen, Celgene, Forward Pharma, Genentech/Roche, Janssen, Merck, Miraca Life Sciences, Napo Pharmaceuticals, Pfizer, Samsung Bioepis, Sandoz, Shire, Takeda
Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda, UCB
Iris Dotan, MD
Consulting Fee: AbbVie, Ferring, Genentech, Janssen, Neopharm, Pfizer, Rafa, Roche, Takeda
Contracted Research: Ferring, Prometheus, Salix, Santarus, Shire, UCB
Speakers Bureau: AbbVie, Falk, Ferring, Genentech, Janssen, Pfizer, Takeda
Bruce E. Sands, MD, MS
Consulting Fee: AbbVie, Allergan, Amgen, Arena Pharmaceuticals, Boehringer-Ingelheim, Capella Bioscience, Celgene, EnGene, Ferring, Gilean, Janssen, Lilly, Lyndra, MedImmune, Oppilan, Otsuka, Palatin Technologies, Pfizer, Rheos Medicines, Seres Therapeutics, Takeda, Target PharmaSolutions, Theravance, TiGenix, Vivelix
Contracted Research: Celgene, Takeda
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2018 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com